Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Novartis | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Novartis

Entry of generic Diovan limits growth

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Novartis

2Q Revenues: $14.5 billion (+2%)

2Q Earnings: $3.3 billion (+3%)

YTD Revenues: $28.5 billion (+2%)

YTD Earnings: $6.5 billion (+2%)

Comments: Pharmaceutical sales were $8.2 billion in the quarter (+1%). Growth was impacted by Japan, which saw a continued decline in Diovan sales, and in the U.S., Diovan inventory destocking ahead of the generic entry in July 2014 also impacted sales. Growth products generated $3.4 billion in sales, up 15%, and included Gilenya, Afinitor, Tasigna, Galvus, Lucentis, Xolair, the COPD portfolioand Jakavi, which contributed 42% of division sales, up from 36% in 2Q13. Currency had a negative impact of 5%, primarily due to the stronger Swiss franc and weakening of emerging market currencies, partly offset by a stronger euro.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters